First patient included in the Pseudovax Trial
After years of planning and preparation, we are proud to share that the first patient in the Pseudovax trial has now received the initial vaccine dose and everything has gone smoothly.
This important milestone was celebrated on Friday, November 14th, together with collaborators, colleagues, and representatives from the user panel, with cake and coffee.
The Pseudovax project was initiated by Professor Kjersti Flatmark and Dr. Else Marit Inderberg following their publication in J Immunother Cancer in 2021. Their work demonstrated that the immune response in patients with PMP against mutated Gsα has been insufficient to control tumor growth, likely due to inhibition of anti-tumor T cells through the up regulation of immune checkpoint molecules.
These findings provide a strong foundation for the trial, exploring vaccination with Gsα peptides in combination with immune checkpoint inhibition as a potential curative treatment for PMP and other cancers driven by GNAS mutations.
The Pseudovax trial is now ongoing at the Clinical Trials Unit at the Radium Hospital with Geir Olav Hjortland MD, PhD as clinical PI.